Epigamia, founded by Rohan Mirchandani, has revolutionized the Indian dairy and health snacking market with its innovative range of Greek yogurts, smoothies, and plant-based offerings. Established in 2015 and headquartered in Mumbai, Epigamia has built a loyal customer base focused on health and wellness. With strong backing from reputed investors, Epigamia is continuously innovating its product lines to cater to evolving consumer preferences. Despite current losses, the company’s rapid revenue growth and expansion strategy position it as a future market leader in India's FMCG sector.
Founding Year | 2015 |
---|---|
Headquarters | Mumbai, India |
Valuation | ₹2,100 Cr (2023) |
Total Funding | ₹505 Cr |
Annual Revenue | ₹260 Cr (FY24) |
Annual Net Profit | ₹-80 Cr (FY24) |
EBITDA Margin | -15% |
Employees | ~400 |
Round | Year | Amount | Investors |
---|---|---|---|
Series A | 2016 | ₹90 Cr | Verlinvest, DSG Consumer Partners |
Series B | 2019 | ₹150 Cr | Danone Manifesto Ventures, Verlinvest |
Series C | 2022 | ₹265 Cr | Lightbox Ventures, Verlinvest |
Epigamia recently launched its vegan yogurt line and signed partnerships with major gym chains to expand its health-oriented consumer base. The brand aims to double its market share by 2026 with new offerings and expanded retail presence.
Metric | Detail |
---|---|
Revenue Growth | ▲ ₹260 Cr in FY24 |
Profitability | ▼ Loss of ₹80 Cr |
Funding | ▲ ₹505 Cr total raised |
Efficiency | ▲ Improved margins to -15% |
Valuation | ▲ ₹2,100 Cr (2023) |
Epigamia continues to innovate and expand in India's fast-growing health snacking segment. While it currently operates at a loss, its strong revenue growth, expanding product portfolio, and investor confidence suggest a strong potential for future profitability and a possible IPO. Make smarter business decisions with verified insights on companies and directors. Visit Affluense.ai to learn more.
Disclaimer: © 2025. All information is curated from public and third-party sources and provided solely for legitimate business use. Please ensure proper authorization before use. The depth of information depends on what is publicly available and may vary between individuals.